204 related articles for article (PubMed ID: 34419505)
1. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC.
Farooqi A; Ludmir EB; Mitchell KG; Antonoff MB; Tang C; Lee P; Chang J; Elamin Y; Gomez DR; Gandhi SJ
Radiother Oncol; 2021 Oct; 163():114-118. PubMed ID: 34419505
[TBL] [Abstract][Full Text] [Related]
2. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
3. A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
Wang X; Zamdborg L; Ye H; Grills IS; Yan D
BMC Cancer; 2018 Oct; 18(1):962. PubMed ID: 30305131
[TBL] [Abstract][Full Text] [Related]
4. Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study.
Chen Y; Wang Y; Yang Z; Hu M; Lu J; Zhang Y; Qian F; Zhang B; Wang S; Wang K; Zhang W; Han B
Thorac Cancer; 2022 Mar; 13(5):732-741. PubMed ID: 35060346
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Petty WJ; Urbanic JJ; Ahmed T; Hughes R; Levine B; Rusthoven K; Papagikos M; Ruiz JR; Lally BE; Chan M; Clark H; D'Agostino RB; Blackstock AW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):527-535. PubMed ID: 30003996
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
7. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
[TBL] [Abstract][Full Text] [Related]
8. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Zhang J; Sepesi B; Vaporciyan AA; Swisher SG; Heymach JV; Zhang J; Gomez DR; Antonoff MB
Clin Lung Cancer; 2020 Jan; 21(1):37-46.e7. PubMed ID: 31447303
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
Hasselle MD; Haraf DJ; Rusthoven KE; Golden DW; Salgia R; Villaflor VM; Shah N; Hoffman PC; Chmura SJ; Connell PP; Vokes EE; Weichselbaum RR; Salama JK
J Thorac Oncol; 2012 Feb; 7(2):376-81. PubMed ID: 22198429
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
11. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
[TBL] [Abstract][Full Text] [Related]
12. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells.
Liu C; Sun B; Hu X; Zhang Y; Wang Q; Yue J; Yu J
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1055-1064. PubMed ID: 31437470
[TBL] [Abstract][Full Text] [Related]
14. Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type.
Hu X; Li H; Liu H; Liu Z; Xia T; Zhang J; Wang Y
Transl Cancer Res; 2021 Jan; 10(1):184-194. PubMed ID: 35116250
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
16. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis.
Petrelli F; Ghidini A; Cabiddu M; Tomasello G; De Stefani A; Bruschieri L; Vitali E; Ghilardi M; Borgonovo K; Barni S; Trevisan F
Lung Cancer; 2018 Dec; 126():194-200. PubMed ID: 30527187
[TBL] [Abstract][Full Text] [Related]
17. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
Gomez DR; Tang C; Zhang J; Blumenschein GR; Hernandez M; Lee JJ; Ye R; Palma DA; Louie AV; Camidge DR; Doebele RC; Skoulidis F; Gaspar LE; Welsh JW; Gibbons DL; Karam JA; Kavanagh BD; Tsao AS; Sepesi B; Swisher SG; Heymach JV
J Clin Oncol; 2019 Jun; 37(18):1558-1565. PubMed ID: 31067138
[TBL] [Abstract][Full Text] [Related]
18. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
Arrieta O; Barrón F; Maldonado F; Cabrera L; Corona-Cruz JF; Blake M; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; García O; Arén O; De la Garza J
Lung Cancer; 2019 Apr; 130():67-75. PubMed ID: 30885354
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
20. Real-World Evidence of Health Outcomes Related to Lung Stereotactic Body Radiation Therapy in Brazil.
Faroni L; Ferreira CG; Moraes F; Baldotto C; Zukin M; Aran V; Araujo LH
JCO Glob Oncol; 2022 Nov; 8():e2200061. PubMed ID: 36351211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
